| Week 0 (baseline) | Week 8 | Week 16 | Week 24 | ||||
---|---|---|---|---|---|---|---|---|
Control (N = 36) | Intervention (N = 33) | Control (N = 28) | Intervention (N = 29) | Control (N = 21) | Intervention (N = 27) | Control (N = 24) | Intervention (N = 27) | |
Hypnotics and sedativesa | 3 (8.3%) | 6 (18.2%) | 4 (14.3%) | 4 (13.8%) | 3 (14.3%) | 4 (14.8%) | 4 (16.7%) | 2 (7.4%) |
Benzodiazepinesb | 10 (27.8%) | 13 (39.4%) | 5 (17.9%) | 13 (44.8%) | 3 (14.3%) | 12 (44.4%) | 5 (20.8%) | 9 (33.3%) |
Antidepressantsc | 21 (58.3%) | 16 (48.5%) | 16 (57.1%) | 11 (37.9%) | 12 (57.1%) | 11 (40.7%) | 14 (58.3%) | 11 (40.7%) |
Antipsychoticsd | 20 (55.6%) | 16 (48.5%) | 17 (60.7%) | 14 (48.3%) | 12 (57.1%) | 12 (44.4%) | 12 (50.0%) | 12 (44.4%) |
Anti-dementia drugse | 7 (19.4%) | 6 (18.2%) | 5 (17.9%) | 5 (17.2%) | 2 (9.5%) | 4 (14.8%) | 4 (16.7%) | 5 (18.5%) |